Related Experiment Video
Updated: Mar 28, 2026

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
MicroRNAs and Gastrointestinal Stromal Tumor
Pinar Akçakaya1,2, Weng-Onn Lui3,4
1Department of Oncology-Pathology, Karolinska Institutet, Stockholm, SE-17176, Sweden. pinar.akcakaya@ki.se.
Abstract:
Gastrointestinal stromal tumor (GIST) is the most commonly diagnosed mesenchymal tumor in the gastrointestinal tract. This tumor type is driven by gain-of-function mutations in receptor tyrosine kinases (such as KIT, PDGFRA, and BRAF) or loss-of-function mutations in succinate dehydrogenase complex subunit genes (SDHx). Molecular studies on GIST have improved our understanding of the biology of the disease and have led to the use of targeted therapy approach, such as imatinib for KIT/PDGFRA-mutated GIST. Recently, microRNAs have emerged as important regulators of KIT expression, cancer cell behavior, and imatinib response in GIST. This chapter aims to provide an overview on current understanding of the biological roles of microRNAs in GIST and possible implications in prognosis and therapeutic response.
Related Concept Videos
MicroRNAs
MicroRNAs
